|
KMID : 0370220190630010001
|
|
Yakhak Hoeji
2019 Volume.63 No. 1 p.1 ~ p.14
|
|
|
Cost Effectiveness of Insulin Glargine/Lixisenatide for Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin in South Korea
|
|
Park Hae-Young
An Se-Na
Park Su-San
Kim Dong-Ha
Kim Hye-Ok
Kwon Jeong-Mi
Kwon Jin-Won
|
|
|
Abstract
|
|
|
|
This study aimed to assess the cost-effectiveness of insulin glargine/lixisenatide (iGlarLixi) in comparison with premixed insulin for patients with basal insulin-uncontrolled type 2 diabetes in South Korea. The CORE Diabetes Model, a Markov model, was used with the following settings: a 30 year horizon, a payer perspective, and a 3% discount rate. Each treatment was assumed to be administered for the first 3 years, and then switched to rescue regimen. The baseline HbA1c and body mass index (BMI) were 8.6 ± 1.3%, and 24.4 ± 3.3 kg/m2, respectively. Indirect treatment comparisons showed that iGlarLixi resulted in significantly greater reduction from baselines for HbA1c and BMI compared with premixed insulin; ?0.50% (95% confidence interval (CI): ?0.68, ?0.32) for HbA1c and ?0.80 kg/m2 (95% CI: ?1.29, ?0.31) for BMI. In the base analysis, iGlarLixi was found to be dominant (more effective and less costly) over premixed insulin with 0.079 additional quality-adjusted life-years and lowered cost by approximately 230 USD, and the incremental cost-utility ratios from sensitivity analyses also remained dominant or below 10,000 USD. This study demonstrated that iGlarLixi was cost effective for treating patients with type 2 diabetes with poor glucose control on basal insulin in comparison with premixed insulin in South Korea.
|
|
|
KEYWORD
|
|
|
Cost-utility analysis, insulin glargine, glucagon-like peptide-1 receptor, diabetes mellitus
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|